Literature DB >> 28250158

Binding of Platelets to Lymphocytes: A Potential Anti-Inflammatory Therapy in Rheumatoid Arthritis.

Carlos Zamora1, Elisabet Cantó2, Juan C Nieto2, Jorge Bardina2, Cesar Diaz-Torné2,3, Patricia Moya3, Berta Magallares3, M Angels Ortiz2, Germà Julià2, Candido Juarez4, Josep M Llobet3, Silvia Vidal1.   

Abstract

Soluble factors released from platelets can modulate the immune response of leukocytes. We and others have recently found that T lymphocytes with bound platelets have reduced proliferation and IFN-γ and IL-17 production. Thus, we speculate that if we induce the binding of platelets to lymphocytes, we will be able to regulate the inflammatory response. When we cocultured platelets with lymphocytes at different ratios, we were able to increase the percentage of lymphocytes with bound platelets. The coculture of platelets with lymphocytes in the presence of stimulation decreased the production of IFN-γ and TNF-α, T cell proliferation, and the expression of CD25, PD-L1, and SLAM. However, this coculture increased CD39 expression. All of these effects were dependent on the dose of platelets and operated indistinctly with platelets from different healthy donors. When platelets were cocultured in the same compartment with lymphocytes, we observed less IFN-γ and TNF-α production and T lymphocyte proliferation than in cultures with platelets separated from lymphocytes by a 0.4-μm pore size filter. The binding of platelets to lymphocytes was blocked with anti-P-selectin Abs, and when this occurred we observed higher IFN-γ and TNF-α production than in nonblocked conditions. The cocultures of platelets with synovial fluid cells from rheumatoid arthritis patients reduced inflammatory cytokine production and increased IL-10 production. These results suggest that platelet binding to lymphocytes effectively regulates T lymphocyte function. This mechanism could be easily applied to reduce inflammatory responses.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28250158     DOI: 10.4049/jimmunol.1601708

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Enhancing functional platelet release in vivo from in vitro-grown megakaryocytes using small molecule inhibitors.

Authors:  Danuta Jarocha; Karen K Vo; Randolph B Lyde; Vincent Hayes; Rodney M Camire; Mortimer Poncz
Journal:  Blood Adv       Date:  2018-03-27

2.  Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents.

Authors:  Carlos Zamora; Mariona Riudavets; Margarita Majem; Silvia Vidal; Georgia Anguera; Letícia Alserawan; Ivana Sullivan; Andrés Barba; Jorgina Serra; M Angels Ortiz; Pablo Gallardo; Lidia Perea; Javier Gavira; Agustí Barnadas
Journal:  Cancer Immunol Immunother       Date:  2021-01-02       Impact factor: 6.968

Review 3.  Autoimmunity in 2017.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

4.  Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study.

Authors:  Ajay Sheshadri; Alberto A Goizueta; Vickie R Shannon; David London; Guillermo Garcia-Manero; Hagop M Kantarjian; Farhad Ravandi-Kashani; Tapan M Kadia; Marina Y Konopleva; Courtney D DiNardo; Sherry Pierce; Abdulrazzak Zarifa; Aya A Albittar; Linda L Zhong; Fechukwu O Akhmedzhanov; Muhammad H Arain; Mansour Alfayez; Ahmad Alotaibi; Mehmet Altan; Aung Naing; Tito R Mendoza; Myrna C B Godoy; Girish Shroff; Sang T Kim; Saadia A Faiz; Dimitrios P Kontoyiannis; Fareed Khawaja; Kristofer Jennings; Naval G Daver
Journal:  Cancer       Date:  2022-04-22       Impact factor: 6.921

5.  "Platelet-rich plasma holds promise in management of rheumatoid arthritis"-systematic review.

Authors:  Girinivasan Chellamuthu; Sathish Muthu; Manish Khanna; Venus Khanna
Journal:  Rheumatol Int       Date:  2021-04-08       Impact factor: 2.631

Review 6.  Moving toward targeting the right phenotype with the right platelet-rich plasma (PRP) formulation for knee osteoarthritis.

Authors:  Isabel Andia; Leire Atilano; Nicola Maffulli
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-03-29       Impact factor: 5.346

Review 7.  Fresh Evidence for Platelets as Neuronal and Innate Immune Cells: Their Role in the Activation, Differentiation, and Deactivation of Th1, Th17, and Tregs during Tissue Inflammation.

Authors:  Eugene D Ponomarev
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

8.  Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors.

Authors:  Alexander B Zaslavsky; M P Adams; X Cao; T Maj; J E Choi; J Stangl-Kremser; S Patel; A Putelo; S K Lee; S Nallandhighal; A Kasputis; A Alva; M Lew; A Qin; R Mehra; T M Morgan; S S Salami; Z Reichert; A Udager; W Zou; Ganesh S Palapattu
Journal:  Sci Rep       Date:  2020-11-09       Impact factor: 4.379

9.  Platelet Induced Functional Alteration of CD4+ and CD8+ T Cells in HNSCC.

Authors:  Christina Polasky; Franziska Wendt; Ralph Pries; Barbara Wollenberg
Journal:  Int J Mol Sci       Date:  2020-10-12       Impact factor: 5.923

10.  Platelet-conditioned media induces an anti-inflammatory macrophage phenotype through EP4.

Authors:  Sean P Heffron; Ada Weinstock; Bianca Scolaro; Shiyu Chen; Brian E Sansbury; Greg Marecki; Christina C Rolling; Hanane El Bannoudi; Tessa Barrett; James W Canary; Matthew Spite; Jeffrey S Berger; Edward A Fisher
Journal:  J Thromb Haemost       Date:  2020-12-03       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.